Insight Molecular Diagnostics Inc. (IMDX) — Analyst outlook / Analyst consensus target is. Based on 11 analyst ratings, the consensus is bullish — 7 Buy, 4 Hold.
The consensus price target is $10.50 (low: $9.00, high: $12.00), representing an upside of 207% from the current price $3.42.
Analysts estimate Earnings Per Share (EPS) of $-2.74 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.66 vs est $-2.74 (missed -70.1%). 2025: actual $-1.65 vs est $-1.15 (missed -44.1%). Analyst accuracy: 64%.
IMDX Stock — 12-Month Price Forecast
$10.50
▲ +207.02% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Insight Molecular Diagnostics Inc., the average price target is $10.50, with a high forecast of $12.00, and a low forecast of $9.00.
The average price target represents a +207.02% change from the last price of $3.42.
Highest Price Target
$12.00
Average Price Target
$10.50
Lowest Price Target
$9.00
IMDX Analyst Ratings
Buy
Based on 11 analysts giving stock ratings to Insight Molecular Diagnostics Inc. in the past 3 months
EPS Estimates — IMDX
64%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$4.66
vs Est –$2.74
▼ 41.2% off
2025
Actual –$1.65
vs Est –$1.15
▼ 30.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — IMDX
53%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.002B
vs Est $0.001B
▲ 73.4% off
2025
Actual $0.004B
vs Est $0.003B
▲ 20.5% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
